Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 13, 2019

View Archived Issues

Role of p300 in BRD4-NUT-driven NUT carcinomas and novel dual BET/p300 bromodomain inhibitors

MAb targeting TREM1+ myeloid cells boosts antitumor immunity and checkpoint inhibitor sensitivity

Prelude initiates phase I study of PRT-811 in advanced solid tumors, gliomas and myelofibrosis

Encouraging results seen in phase II studies of NanoPac paclitaxel

Corcept initiates phase II study of miricorilant for antipsychotic-induced weight gain

Small-molecule STING agonist promotes durable antitumor immunity causing complete tumor regression

Case study points to protective AD gene

RNA controls muscle stem cells

24-week data presented from HMM0301 phase III monotherapy study of dorzagliatin

FDA approves IND for WP-1066

FDA places on hold the phase I/II IGNITE DMD study of SGT-001

New data presented for ParvOryx in human ovarian cancer explants

DCC-3116 as a promising inhibitor of autophagy in preclinical models of RAS-mutant cancers

Preclinical and preliminary first-in-human data presented for STRO-002

Chugai Pharmaceuticals presents phase I data for EOS-789

SentiBio presents novel allogenic cell therapy, SENTI-101

KD-025 meets primary endpoint at interim analysis of pivotal ROCKstar study in chronic GvHD

Positive data presented from initial cohort of phase IIb study of ORMD-0801 in T2D

Virginia Tech Intellectual Properties describes mitochondrial uncouplers

Celgene patents compounds for diffuse large B-cell lymphoma

Macrocyclic oligopeptides identified at Roche

Vertex, Merck & Co. describe endoplasmic reticulum stress inducers

New P2X7 receptor antagonists identified at Shionogi

Break out the sparkling apple cider for DUR-928 alcoholic hepatitis data

New exploratory phase I/II study in Japan assesses NS-089 in Duchenne muscular dystrophy

Bellerophon reports initial data from acute hemodynamic study of INOpulse

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...